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Over the past few years there have been considerable
advances in our understanding of the physiological
regulation of mineral homeostasis. One of the most
important breakthroughs is the identification of fibroblastic
growth factor 23 (FGF23) and its role as a key regulator of
phosphate and 1,25-dihydroxyvitamin D metabolism. FGF23
exerts its biological functions by binding to its cognate
receptor in the presence of Klotho as a cofactor. FGF23
principally acts on the kidney to induce urinary phosphate
excretion and suppresses 1,25-dihydroxyvitamin D synthesis,
thereby indirectly modulating parathyroid hormone
secretion. FGF23 also acts directly on the parathyroid to
decrease parathyroid hormone synthesis and secretion. In
patients with chronic kidney disease, FGF23 levels increase
progressively to compensate for phosphate retention, but
these elevated FGF23 levels fail to suppress the secretion
of parathyroid hormone, particularly in the setting of uremia.
Recent data suggest that this parathyroid resistance to FGF23
may be caused by decreased expression of Klotho–FGFR1
complex in hyperplastic parathyroid glands. This review
summarizes recent insights into the role of FGF23 in mineral
homeostasis and discusses the involvement of its direct and
indirect interaction with the parathyroid gland, particularly
focusing on the pathophysiology of secondary
hyperparathyroidism in chronic kidney disease.
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The parathyroid gland plays an important role in the regulation
of mineral homeostasis by cross talking with other organs such
as the kidney and bone. Fluctuation in extracellular calcium
ion levels is sensed by the parathyroid calcium-sensing
receptors (CaSRs) and subsequently regulates the synthesis
and secretion of parathyroid hormone (PTH).1 PTH acts on
the bone to increase the efflux of calcium and phosphate, and
acts on the kidney to reduce urinary calcium excretion,
inhibit phosphate reabsorption, and stimulate the production
of 1,25-dihydroxyvitamin D (1,25(OH)2D). The increased
1,25(OH)2D acts on the small intestines to increase dietary
absorption of calcium and phosphate and also acts on
the parathyroid gland to inhibit PTH synthesis thereby
closing a negative feedback loop.2,3 These biological effects
of 1,25(OH)2D are mediated by binding of 1,25(OH)2D to
its specific receptor, the vitamin D receptor (VDR), and
subsequent regulation of the transcription by promoter
vitamin D response elements.4 The effect of PTH to promote
phosphate excretion offsets the 1,25(OH)2D-mediated
dietary phosphate absorption and the PTH-mediated phos-
phate efflux from bone. Increase in serum phosphate also
directly stimulates the secretion of PTH through a putative
extracellular phosphate sensor, which in turn acts on the
kidney to promote phosphaturia and thereby prevents
hyperphosphatemia.5
Recently, fibroblastic growth factor 23 (FGF23), a novel
bone-derived hormone, has been identified that has a
physiological role in regulating mineral homeostasis.6
FGF23 principally functions as a hormone regulating
phosphaturia and renal 1,25(OH)2D production,
6–8 suggest-
ing that this circulating factor also mediates secretion of PTH
at least indirectly by regulating serum phosphate and
1,25(OH)2D levels. Importantly, recent experimental studies
have shown that FGF23 also exerts a direct effect on
the parathyroid gland to suppress PTH synthesis and
secretion,9,10 further enhancing our understanding of the
mechanisms that govern mineral metabolism in normal
physiology and various disorders. In this review, we present
recent insights into the role of FGF23 in mineral homeostasis
and discuss its direct and indirect interaction with the
parathyroid gland. We also examine the involvement of
FGF23–parathyroid interaction in the pathophysiology of
mineral disturbances, particularly focusing on secondary
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hyperparathyroidism (SHPT) in patients with chronic kidney
disease (CKD).
FIBROBLAST GROWTH FACTOR 23
FGF23 is a 32-kDa protein that is secreted mainly by
osteocytes in bone.11 It was first cloned in mice as a new
member of FGF family12 and subsequently identified as a
causative humoral factor for autosomal-dominant hypopho-
sphatemic rickets/osteomalacia13 and tumor-induced osteo-
malacia.14 It induces urinary phosphate excretion by
suppressing the expression of sodium/phosphate cotranspor-
ter.7,8 It also suppresses 1,25(OH)2D by inhibition of
1a-hydroxylase (CYP27B1) that converts 25-hydroxyvitamin
D (25(OH)D) to 1,25(OH)2D and stimulation of 24-
hydroxylase (CYP24) that converts 1,25(OH)2D to inactive
metabolites in the proximal tubule of the kidney.7,8
Circulating FGF23 level ranges 25–50 pg/ml in normal
subjects using an intact FGF23 assay, whereas this level is
increased to 10- to 20-fold in patients with hypopho-
sphatemic rickets syndromes.13,14 Excess FGF23 results in
renal phosphate wasting, inappropriately low levels of
1,25(OH)2D, and osteomalacia.
15–18 In contrast, depletion
of FGF23 leads to hyperphosphatemia, excessive levels of
1,25(OH)2D, and soft tissue calcification.
19–23 FGF23 is
proteolytically processed to generate N-and C-terminal
fragments. Neither of the processed N-or C-terminal
fragments of FGF23 can exert its hormonal effects.24 Indeed,
in patients with hereditary diseases of FGF23 deficiency,
augmented production of C-terminal fragments fails to
ameliorate hyperphosphatemia and hypervitaminosis D.21–23
FGF23 exerts its biological functions by binding to its
cognate fibroblastic growth factor receptor (FGFR) in the
presence of its coreceptor Klotho.25,26 Klotho is a transmem-
brane protein that determines the tissue specificity of FGF23.
The N-terminal region of FGF23 binds to and activates FGFR
whereas the C-terminal region of FGF23 is necessary for
interaction with Klotho.27,28 These facts clearly explain why
Klotho null mice display a phenotype identical to that of
Fgf23 null mice, both of which are characterized by
premature aging-related phenotypes associated with hyper-
phosphatemia and paradoxically high 1,25(OH)2D levels.
19,29
Indeed, the administration of FGF23 to either Klotho
knockout mice or Klotho/Fgf23 double knockout mice does
not produce its phosphaturic and 1,25(OH)2D-inhibitory
effect.30 Recent studies also showed that genetic inactivation
of Klotho in either Hyp mice, a murine homolog of X-linked
hypophosphatemic rickets, or Fgf23 transgenic mice resulted
in hyperphosphatemia and increased 1,25(OH)2D levels, a
phenotype consistent with Fgf23-ablated mice, further
emphasizing the in vivo importance of Klotho in FGF23
action.31,32
Among multiple FGFR isoforms, Klotho can bind with
FGFR1c, 3c, and 4 and increase their affinity to FGF23
in vitro.27 However, a functional analysis has shown that
Klotho-dependent FGF23 signaling defined by upregulation
of the gene early growth-responsive 1 (Egr-1) is restricted to
interaction with FGFR1c.28 Recent in vivo studies have also
shown that neither FGFR3 nor FGFR4 is the principal
mediator of the FGF23 effects in the kidney,33 supporting
the possibility that FGFR1c is the physiologically relevant
target for FGF23 in vivo. It is, however, still unclear how
in the kidney FGF23 exerts its physiological effects on
the proximal tubule despite the highest expression of
Klotho–FGFR1c complexes in the distal tubule. FGF23
actions on the proximal tubule may be mediated by FGF23
stimulation of the distal tubule and subsequent distal–
proximal tubule interaction, but further researches are
needed to confirm this possibility.
FGF23 secretion is regulated by several systemic factors.
Given the hormonal effect of FGF23 to regulate renal
phosphaturia and 1,25(OH)2D production, its secretion
should be regulated by serum phosphate and/or
1,25(OH)2D levels. The former possibility is supported by
experimental studies showing that dietary phosphate loading
in mice leads to an increase in bone FGF23 mRNA and serum
FGF23,34 although this effect is rather modest in humans.35,36
It is, however, still unclear how extracellular phosphate is
sensed by the body and whether this sensing mechanism is
involved in the regulation of FGF23 secretion. On the other
hand, there is concrete evidence that 1,25(OH)2D stimulates
FGF23 production both in vivo and in vitro, through vitamin
D-response elements present in the FGF23 promoter.37 A
clinical study also showed that administration of 1,25(OH)2D
to patients undergoing dialysis results in increase in serum
FGF23 levels.38 More recently, estrogen is identified as a novel
positive regulator of FGF23 secretion. Estrogens increase
FGF23 synthesis both in vivo and in vitro, which may in part
explain the effect of estrogens to decrease serum 1,25(OH)2D
and phosphate levels.39 FGF23 secretion is also regulated by
several local bone-derived factors, such as phosphate-
regulating gene with homologies to endopeptidases on the
X chromosome, dentin matrix acidic phosphoprotein 1 and
matrix extracellular phosphoglycoprotein, although their
precise interactions remain to be elucidated.6
FGF23 AND THE PARATHYROID GLAND
The parathyroid gland also expresses Klotho and FGFR1 and
is a target for FGF23. This novel FGF23–parathyroid
interaction is primarily suggested by the effects of recombi-
nant FGF23 to upregulate the expression of Egr-1 in the
parathyroid gland of rats.28 However, until recently, it has
been a matter of debate whether FGF23-dependent pathways
stimulate or inhibit PTH secretion. In patients and animal
models of excess FGF23 production, serum levels of PTH
have been variably reported but were most frequently
elevated.15–18 A translocation causing increased Klotho level
results in severe hyperparathyroidism associated with in-
creased FGF23 levels.40 Furthermore, in patients with CKD,
elevated FGF23 levels are associated with PTH hypersecre-
tion.41,42 However, whether the elevated PTH levels seen in
these cases are the direct result of increased FGF23 is
difficult to discern, because FGF23-mediated reductions in
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1,25(OH)2D might also have a role in dysregulated PTH
secretion.
Recently, the direct effect of FGF23 on the parathyroid
gland has been uncovered by two independent research
groups.9,10 One study showed that FGF23 acts directly on the
parathyroid to activate the mitogen-activated protein kinase
pathway and thereby decrease PTH gene expression and
secretion both in vivo in rats and in vitro in rat parathyroid
cultures.9 Another study used primary cultures of bovine
parathyroid cells and showed that FGF23 decreases PTH
secretion, which may be partly mediated by increased
parathyroid CYP27B1 expression.10 These data conclusively
show that FGF23 acts directly on the parathyroid gland to
decrease PTH secretion (Figure 1). Importantly, this direct
effect of FGF23 to inhibit PTH secretion is in contrast to its
indirect effect by inhibition of renal 1,25(OH)2D production,
suggesting that the systemic effect of FGF23 on parathyroid
function can be varied under different conditions. This
complex regulation of PTH secretion by FGF23 may in part
explain the discrepancy in PTH levels observed in humans
and experimental animals of FGF23 excess (Figure 2).
ROLE OF FGF23 IN CKD
Traditionally, the disturbed mineral and bone homeostasis in
CKD has been viewed from the perspective of the PTH-
vitamin D axis, where the progressive reduction in
1,25(OH)2D synthesis as a result of decreased renal mass
along with a functional inhibition of CYP27B1 by hyperpho-
sphatemia has a major role in the pathogenesis of SHPT.43
However, the observation that 1,25(OH)2D levels begin to
decline long before the development of hyperphosphatemia
give cause to reconsider the traditional view of SHPT. In this
regard, the identification of FGF23 provides important
implications for the understanding of abnormal mineral
metabolism in CKD. In patients with CKD, circulating levels
of FGF23 are progressively increased as kidney function
declines.44 This increase in serum FGF23 levels cannot be
explained solely by the accumulation of C-terminal frag-
ments, because a subsequent study showed a similar increase
by use of the intact assay that exclusively detects the full-
length, biologically active molecule.45 Thus, it is reasonable
to consider that in patients with CKD, FGF23 production
is increased to counteract chronic phosphate retention by
promoting urinary phosphate excretion in the face of
reduced nephron mass.
Notably, in this setting, a previous study has shown that
FGF23 was a strong independent predictor of diminished
1,25(OH)2D levels even after adjustment for renal function,
serum phosphate levels, and 25(OH)D levels.46 This finding
suggest that in patients with CKD, increased FGF23 to
maintain neutral phosphate balance results in suppression of
renal 1,25(OH)2D production and thereby triggers the early
development of SHPT. In advanced stage of CKD, dietary
phosphate may overcome such compensation for decreased
nephron mass despite markedly elevated FGF23 levels. This
results in overt hyperphosphatemia and 1,25(OH)2D defi-
ciency, both of which further stimulate PTH secretion and
parathyroid cell proliferation, leading to the development of
uremic parathyroid hyperplasia.47
FGF23 also is important in the pathogenesis of post-
transplant hypophosphatemia. This complication has been
long thought to be caused by tertiary hyperparathyroidism,48
but this PTH-centric view cannot explain the concomitant
1,25(OH)2D deficiency and the development of urinary
phosphate wasting even in the absence of elevated PTH levels.
In this context, recent data suggest that FGF23 rather than
PTH is the primary factor accounting the syndrome of
posttransplant hypophosphatemia and inappropriately low
1,25(OH)2D levels.
49–52 In the pretransplant period, FGF23
secretion is extremely increased to counteract chronic
phosphate retention but fails to exert its hormonal effects
in the absence of functioning kidney. However, after kidney
transplantation, this excess FGF23 acts on the allograft to
promote phosphaturia and suppress 1,25(OH)2D produc-
tion. Importantly, this FGF23-centric view may imply the
limitation of current management strategies using high doses
of phosphate supplements and active vitamin D sterols, both
of which further stimulate FGF23 secretion.49 In this regard,
it is promising that the use of recently developed anti-FGF23
monoclonal antibodies is therapeutically effective for Hyp
mice.53 This insight may open new therapeutic strategies of












Figure 1 | FGF23 signaling in the parathyroid cell. FGF23 can
bind to the Klotho–FGFR1c complex on the surface of the parathyroid
cell and thereby triggers downstream signaling. This results
in the activation of ERK and the induction of Egr-1 expression,
leading to inhibition of PTH gene expression and secretion.
CaSR, calcium-sensing receptor; Egr-1, early growth-responsive 1;
ERK, extracellular signal-regulated kinase; FGF23, fibroblastic
growth factor 23; FGFR1c, fibroblastic growth factor receptor 1c;
PTH, parathyroid hormone; VDR, vitamin D receptor.
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FGF23 AND UREMIC PARATHYROID HYPERPLASIA
Parathyroid hyperplasia is one of the characteristic features of
patients with end-stage renal disease.54 It can be divided into
two types with different morphological features, that is,
diffuse and nodular hyperplasia. Initially, in patients with
CKD, several factors such as phosphate retention, decreased
1,25(OH)2D, and resulting hypocalcemia act on the para-
thyroid cells to proliferate, leading to diffuse hyperplasia.
Some cells proliferate more vigorously, forming small
nodules each of which is monoclonal in origin. These
nodules become grossly enlarged and exhibit a nodular
hyperplasia.55 Importantly, both CaSR and VDR are
progressively downregulated in the course of parathyroid
hyperplasia,56–58 which is considered to explain the resistance
to active vitamin D therapy in advanced SHPT.
Several observational studies have shown that in patients
undergoing dialysis FGF23 levels are extremely increased in
association with the severity of SHPT and/or hyperpho-
sphatemia.38,41,42 Such a marked elevation in FGF23 levels
may in part be attributed to active vitamin D treatment,38 in
addition to other possible factors such as impaired renal
FGF23 degradation and chronic phosphate retention. It is not
clear whether PTH-induced phosphate release from bone
stimulates FGF23 secretion. Not surprisingly, the source of
increased FGF23 is bone cells, but not parathyroid cells,
even in patients with advanced parathyroid hyperplasia.41
This fact is in line with the observation that parathyroidect-
omy for patients with advanced parathyroid hyperplasia
results in gradual, but not rapid, decline in serum FGF23
levels.59 The mechanism of this FGF23 decline is not clear,
but it may be attributed to decreased serum phosphate levels
as a result of increased phosphate influx into bone after
parathyroidectomy.
In this context, it is of particular interest that pretreatment
serum FGF23 levels predict the effectiveness of active vitamin
D therapy and the future development of refractory
hyperparathyroidism in dialysis patients with SHPT.41,42
The mechanism of this finding is not clear; however, recent
studies suggest that FGF23 is a more sensitive biomarker of
disordered phosphate metabolism than concomitant serum
phosphate measurements.60 Given that high phosphate




















Figure 2 | FGF23–parathyroid interaction in hypophosphatemic disorders due to excess FGF23 secretion. Excess FGF23 acts on the
kidney to induce urinary phosphate excretion and suppress renal production of 1,25(OH)2D. In this setting, FGF23-mediated
hypophosphatemia acts to suppress PTH secretion, whereas FGF23-mediated low 1,25(OH)2D acts to stimulate PTH secretion. FGF23 also
acts directly on the parathyroid to inhibit PTH synthesis and secretion. This complex regulation of PTH secretion by FGF23 may explain the
discrepancy in PTH levels observed in hypophosphatemic disorders due to excess FGF23 secretion. 1,25(OH)2D, 1,25-dihydroxyvitamin D;
FGF23, fibroblastic growth factor 23; PTH, parathyroid hormone.
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proliferation,5 it can be deduced that chronic phosphate
retention as reflected by elevated FGF23 levels may contribute
to further progression of parathyroid hyperplasia. Another
possibility is that high levels of FGF23 at baseline may be a
consequence of prolonged active vitamin D administration
for severe SHPT, which may lead to future resistance to this
therapy. Regardless, additional studies are needed to translate
these findings into the development of novel therapeutic
approaches. In addition, whether FGF23 stimulation or
suppression is beneficial or potentially harmful is also crucial
and worthy of further investigation.61
Another issue that should be addressed is how to
extrapolate recent data showing that FGF23 is a negative
regulator of parathyroid function9,10 in patients with CKD.
Specifically in uremic patients undergoing dialysis, the
indirect action of FGF23 to promote PTH secretion by
decreased 1,25(OH)2D may be less evident, because renal
production of 1,25(OH)2D is substantially impaired and
active vitamin D sterols are frequently used to control SHPT.
Nevertheless, in these patients, PTH secretion remains
elevated despite extremely high FGF23 levels.38,41,42,59 This
fact suggests the presence of resistance to FGF23 action in
uremic patients. One possible explanation for this resistance
is that some uremic toxins that accumulate in renal
failure interfere with interaction between FGF23 and
Klotho–FGFR1c complex and/or subsequent intracellular
signaling, in a manner analogous to erythropoietin resistance
in renal anemia and skeletal resistance to PTH in low-
turnover bone disease. Another possibility is that the
expression of Klotho–FGFR1c complex may be decreased in
uremic parathyroid hyperplasia, as has been reported
previously in association with CaSR and VDR.56–58 To
investigate this possibility, we have recently examined the
expression of Klotho and FGFR1 in surgically excised
parathyroid glands of uremic patients. Compared with
normal tissue, the expression of Klotho and FGFR1 decreased
significantly in hyperplastic parathyroid glands, particularly
in glands with nodular hyperplasia.62 This result suggests that
the depressed expression of the Klotho–FGFR1c complex in
hyperplastic glands may explain the resistance to extremely
high FGF23 levels in uremic patients (Figure 3). Indeed,


































Figure 3 | FGF23–parathyroid interaction in chronic kidney disease. In patients with chronic kidney disease, serum FGF23 is increased
to maintain neutral phosphate balance, but this leads to suppression of renal 1,25(OH)2D production and thereby triggers the early
development of secondary hyperparathyroidism. Progression to renal failure may overcome this compensation for decreased nephron mass
and result in overt hyperphosphatemia, which further stimulates PTH secretion and parathyroid cell proliferation, leading to parathyroid
gland hyperplasia characterized by enlargement of the parathyroid glands. In this setting, markedly increased FGF23 should act on
the parathyroid as a negative regulator but fails to suppress PTH secretion. This resistance of parathyroid to FGF23 may be caused
by downregulation of Klotho–FGFR1c complex. 1,25(OH)2D, 1,25-dihydroxyvitamin D; CaSR, calcium-sensing receptor; FGF23, fibroblastic
growth factor 23; FGFR1c, fibroblastic growth factor receptor 1c; PTH, parathyroid hormone; VDR, vitamin D receptor.
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showing that FGF23 does not inhibit PTH secretion both
in vivo CKD rats and in vitro parathyroid gland cultures
from CKD rats (abstract; Rodriguez M, et al. J Am Soc
Nephrol 2009; 20: 53A and Galitzer H, et al. J Am Soc
Nephrol 2009; 20: 53A). Whether downregulation of the
Klotho–FGFR1c complex has a role in the pathogenesis of
SHPT and whether this expression is mediated by other
factors involved in the disorder would be worthy of future
investigation.
CONCLUSION
The identification of FGF23 and the clarification of its role as
a key regulator of phosphate and 1,25(OH)2D has greatly
enhanced our knowledge of the physiological regulation of
mineral homeostasis. These insights have important implica-
tions for understanding the pathophysiology of not only rare
disorders such as renal phosphate wasting disorders but also
more common mineral and bone disorders associated with
CKD. Furthermore, the recent data on the direct interaction
between FGF23 and the parathyroid gland further stimulate
the research interest in the pathogenesis of uremic para-
thyroid hyperplasia, where PTH synthesis and secretion
remains stimulated despite extremely high FGF23 levels. It is
hoped that the translation of these insights into new
therapeutic agents and biomarkers improves the outcomes
of patients suffering from disturbed mineral homeostasis.
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